The remainder of this file is divided into four parts:
PART I. What do people say about Super Blue Green Algae?
Here's a few quotes collected from both Cell Tech
promotional literature and the FDA file on Cell Tech.
There's remarkable agreement between these two sources
on the effects of the algae. Capitalization added.
Quoting from _Personal_Experiences_with_Super_Blue_
_Green_Algae_ (Cell Tech promotional literature):
"On my initial consumption I felt better than ever,
having incredible energy and elation. The excitement
of it KEPT ME UP MOST OF THE NIGHT, yet that day
at work I was without fatigue." -- C.H.
"Since I've been taking Super Blue Green Algae
I experience very little jet-lag, sleep well, feel
more alert than exhausted on a long flight. Fellow
flight attendants are ASTOUNDED WITH MY ENERGY LEVEL!"
-- L.L.D.
"When he was in the eighth grade, we decided to give him
the Super Blue Green Algae. And we didn't tell anyone,
because we didn't want there to be any bias. He took
about six capsules, three Omega Sun and three Alpha Sun."
"At the end of two weeks three teachers called me and
asked me, 'What are you doing different, Mrs. D?
Is Ricky BACK ON A DRUG or something?' They said his
work had dramatically improved. His attention span
was better, his concentration had increased, he was
responding and his school work was getting done and it
was accurate." -- Mrs. D.
"We have begun to suggest Super Blue Green Algae to
clients WITHDRAWING FROM COCAINE, with excellent results.
It helps them through the depression and cravings
connected with KICKING COCAINE." -- Robert Marrone, PhD,
Sierra Center for the Healing Arts, Nevada City, CA.
Quoting from the official FDA Complaint/Injury Report
on Cell Tech, October 31, 1995, filed by Lina Cicchetto,
Consumer Complaint Coordinator:
"Product was supposed to be used in this manner: for
the first week take digestive enzymes with spectrabiotics
capsule 2 a day increasing weekly. For energy, after
a week add to the initial capsules one capsule of the
'Blue Green Algae' capsule."
"She [the complainant] did this for a week then she added
the algae, the first day she felt very energized, but did
not sleep, next day she was so wired she COULD NOT SLEEP
FOR A WEEK."
Quoting from the official FDA Complaint/Injury Report
on Cell Tech, October 6, 1995, filed by Karen L. Robles,
Consumer Safety Officer:
"Complainant began taking blue-green algae product and
after 10 months felt no benefits. She stopped taking
the product and has had an ENERGY IMBALANCE since that
time. She has been suffering WITHDRAWL and energy
imbalance."
Quoting from the official FDA Complaint/Injury Follow-Up
Report on Cell Tech, November 24, 1995, filed by Susan R.
Nelson, Supervisory Consumer Safety Officer:
"She [the complainant] stated she did not feel the
benefits and quit taking the product (she was still taking
the ------). She immediately had an ENERGY CRASH and had
to stay in bed for a week, she couldn't get out of bed.
---------- stated she felt the algae had an ADDICTIVE
effect on her and she has not felt the same since she quit
the product."
Quoting from the official FDA Complaint/Injury Report
on Cell Tech, April 4, 1995, filed by Cecilia Wolyniak,
Division of Emergency and Enforcement Operations [quoting
a complainant]:
"I believe Cell Tech's algae is a POWERFUL DRUG which
must be regulated by the FDA. Further, the Oregon
Department of Agriculture has cited Cell Tech for rat
droppings in the storage areas and for a substantial
number of insect parts in the product. It is difficult
to believe that the FDA would permit a company like Cell
Tech to sell what I believe to be a POTENT DRUG, under the
guise of the label of 'food supplements,' under DSHEA of
1994 without oversight, monitoring, control and mandated
safety testing. Simple logic would dictate that in
addition to efficacy safety testing, the FDA would not
permit a Merck, Squibb or a Genentech to allow insect
particles in their products sanctioned by the FDA or
permit rat droppings in their product storage areas."
PART II. What is anatoxin-a?
Quoting from _Toxicon_, volume 17, "Pharmacology of
Anatoxin-a, Produced by the Freshwater Cyanophyte
_Anabaena_flos-aquae_ NRC-44-1", by Carmichael, Biggs, and
Peterson, 1979, page 229:
"Anatoxin-a (formerly called very fast death factor) is
the term being used for the potent alkaloid neurotoxin
produced by the freshwater cyanophyte _Anabaena_flos-
aquae_ (Lyngb.) de Bre'b. clone number NRC-44-1."
"Its pharmacological properties have been investigated and
compared with that of a synthetic anatoxin-a which was
derived from L-cocaine."
"Anatoxin-a is a potent depolarizing neuromuscular
blocking agent possessing both muscarinic and nicotinic
activity."
Quoting from page 236:
"Structurally, anatoxin-a does not resemble decamethonium
but instead is similar to the tropane alkaloids,
specifically cocaine."
Quoting from _Molecular_Pharmacology_, volume 18,
"Anatoxin-a: A Novel, Potent Agonist at the Nicotinic
Receptor", by Spivak, Witkop, and Albuquerque, 1980, page
391:
"The potencies of six nicotinic agonists are compared
(Table 2) for their ability to depolarize the frog's
sartorius muscle by 10 mV. Interpolations from data
published by other authors are cited to show that
_anatoxin-a_is_the_most_potent_of_these_six_agonists_."
[Italics in the original.]
[An agonist is a molecule that binds to the same receptor.
Agonists activate the receptor, while antagonists are non-
activating and block the binding of the normal activating
molecule, hence inhibit the action of the receptor.]
Quoting from _The_Journal_of_Pharmacology_and_
_Experimental_Therapeutics_, volume 259, number 1,
"Nicotinic Pharmacology of Anatoxin Analogs. I. Side
Chain Structure-Activity Relationships at Peripheral
Agonist and Noncompetitive Antagonist Sites", by Swanson,
Aronstam, Wonnacott, Rapoport, and Albuquerque, 1991, page
378:
"Anatoxin-a analogs with 12 different modifications of the
'acetyl' side chain moiety or a site directly influencing
the conformation of this moiety were synthesized and
evaluated pharmacologically. Fortunately, this
extraordinary toxin has a semi-rigid homotropane skeletal
structure that restricts the number of stable
conformations."
Quoting from page 383:
"Several modifications of the side chain in anatoxin-a
significantly changed the agonistic properties of the
neurotoxins at the acetylcholinesterase receptor. No
analog thus far tested _in_vitro_ was as potent as the
parent compound anatoxin-a."
Quoting from _The_Journal_of_Pharmacology_and_
_Experimental_Therapeutics_, volume 259, number 1,
"Nicotinic Pharmacology of Anatoxin Analogs. II. Side
Chain Structure-Activity Relationships at Neuronal
Nicotinic Ligand Binding Sites", by Wonnacott, Jackman,
Swanson, Rapoport, and Albuquerque, 1991, pages 390-391:
"Such analysis assumes greater urgency with the
realization that brain acetylcholinesterase receptors
identified by high-affinity tritiated agonist binding are
decreased in Alzheimer's disease (see Kellar and
Wonnacott, 1990), and that nicotine treatment has given an
encouraging result with respect to cognitive performance
in Alzheimer patients (Sahakian _et_al_, 1989, 1990).
Thus, centrally acting nicotinic agents could have an
important therapeutic future in the symptomatic treatment
of Alzheimer's disease (see Kellar and Wonnacott, 1990).
Anatoxin-a is a useful core structure for such drug design
because, as a secondary amine, it readily crosses the
blood brain barrier."
Quoting from _Journal_of_Neurochemistry_, volume 60,
number 6, "(+)-Anatoxin-a Is a Potent Agonist at Neuronal
Nicotinic Acetylcholine Receptors", by Thomas, Stephens,
Wilkie, Amar, Lunt, Whiting, Gallagher, Pereira, Alkondon,
Albuquerque, and Wonnacott, 1993, page 2308:
"In these diverse preparations, (+)-anatoxin-a was between
three and 50 times more potent than (-)-nicotine and
about 20 times more potent than acetylcholine, making it
the most efficacious nicotinic agonist thus far
described."
And a surprise quote from page 2310:
"These studies were supported by grants from the R. J.
Reynolds Tobacco Co. . . ."
PART III. Where does anatoxin-a come from?
Quoting from _Toxicon_, volume 17, "Pharmacology of
Anatoxin-a, Produced by the Freshwater Cyanophyte
_Anabaena_flos-aquae_ NRC-44-1", by Carmichael, Biggs, and
Peterson, 1979, page 229:
"Toxic strains of freshwater cyanophytes have been
implicated in animal poisonings for many years.
_Anabaena_flos-aquae_, _Microcystis_aeruginosa_, and
_Aphanizomenon_flos-aquae_ are the most common species
responsible with the most recent reviews on the subject
written by Moore (1977) and Gentile (1971)."
Quoting from _Journal_of_Applied_Phycology_, volume 5,
number 6, "Anatoxin-a concentration in _Anabaena_ and
_Aphanizomenon_ under different environmental conditions
and comparison of growth by toxic and non-toxic _Anabaena_
strains: a laboratory study.", by Rapala, Sivonen,
Luukkainen, and Niemela, 1993, page 581:
"Anatoxin-a-concentration in cells of _Anabaena_ and
_Aphanizomenon_-strains and in their growth media were
studied in the laboratory in batch cultures at different
temperatures, light fluxes, orthophosphate and nitrate
concentrations and with different nitrogen sources for
growth."
"The amount of toxin in the cells of the toxic strains was
high, often exceeding 1% of their dry weight."
"The highest light flux studied did not limit the growth
or decrease the level of the toxin in the cells of
_Aphanizomenon_."